Latest Hotspot

Atom Bioscience begins enrolling U.S. participants in a worldwide Phase 2b/3 study of an experimental chronic gout therapy

28 April 2024
2 min read

Atom Bioscience, a biotechnology firm in the clinical stage, focused on innovative therapies for metabolic and inflammatory conditions, has initiated patient enrollment across the United States for a Phase 2b/3 study of ABP-671. This new treatment, an orally administered URAT1 inhibitor, targets chronic gout. To date, the trial has incorporated 36 locations spanning 17 states.

👇Explore more about this drug by clicking the image below. Gain detailed insights into its R&D Status, Core Patent, Clinical Trials and Global Approval Status. Stay informed and updated.

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

A globally distributed multicenter trial, which is double-blind and randomized, plans to recruit 580 participants. The first phase of this trial focuses on assessing the safety and effectiveness of various doses and administration patterns of ABP-671, comparing these to either placebo or allopurinol, which is presently the preferred treatment for gout management in the U.S. The second phase of the experiment will examine selected dosing protocols of ABP-671 from the first part on a different group of patients not previously involved in the initial phase.

Gout represents a commonly encountered form of inflammatory arthritis, triggered by prolonged hyperuricemiaa condition where serum uric acid levels exceed 7 mg/dL.

The impact of gout on individual well-being is significant, elevating risks such as sudden cardiac death. The currently available medications for chronic gout are often inadequate in terms of efficacy and carry substantial risks, including potential for kidney failure, sudden cardiac death, and severe liver toxicity.

👇Explore the latest research progress on drug-related developments, indications, therapeutic organizations, clinical trials, results, and patents by clicking on the targeted picture link below. Unfold a world of comprehensive information on this target in just a click!

图形用户界面, 表格

描述已自动生成

According to the data provided by the Synapse Database, As of April 28, 2024, there are 42 investigational drugs for the URAT1 target, including 20 indications, 55 R&D institutions involved, with related clinical trials reaching 238, and as many as 1216 patents.

ABP-671 is a small molecule drug that targets URAT1 and is being developed by Jiangsu Atom Bioscience & Pharmaceutical Co., Ltd. It is currently in Phase 2/3 of clinical development and shows potential for treating gout, hyperuricemia, and chronic kidney diseases. The drug's therapeutic areas encompass a wide range of conditions, indicating its potential for broader applications in the field of biomedicine.

图形用户界面, 文本, 应用程序

描述已自动生成

Pharma Frontiers: Daily Digest of Global Pharmaceutical News - April 27
Pharma Frontiers
10 min read
Pharma Frontiers: Daily Digest of Global Pharmaceutical News - April 27
28 April 2024
April 27th latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.
Read →
Endeavor BioMedicines Secures $132.5M in Oversubscribed Series C to Advance Medical Pipeline
Latest Hotspot
3 min read
Endeavor BioMedicines Secures $132.5M in Oversubscribed Series C to Advance Medical Pipeline
28 April 2024
Endeavor BioMedicines has successfully secured $132.5 million in an oversubscribed Series C funding round to progress their groundbreaking medical pipeline.
Read →
What clinical indicator is BCVA?
"What" Series
2 min read
What clinical indicator is BCVA?
28 April 2024
BCVA stands for Best Corrected Visual Acuity, which is a key indicator commonly used in ophthalmic clinical trials to evaluate a patient's visual acuity.
Read →
Arrowhead Pharmaceuticals Initiates Phase 1/2a Trial of ARO-CFB for Kidney Diseases Linked to Complement System Dysfunctions
Latest Hotspot
3 min read
Arrowhead Pharmaceuticals Initiates Phase 1/2a Trial of ARO-CFB for Kidney Diseases Linked to Complement System Dysfunctions
26 April 2024
Arrowhead Pharmaceuticals has started a Phase 1/2a trial for ARO-CFB aimed at treating kidney diseases caused by complement system dysfunctions.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.